Cancer Therapy via Intranasal Administration of Filamentous Phages
Innovative Products and Technologies
Technology Offer
Cancer Therapy via Intranasal Administration of Filamentous Phages
- RAMOT at Tel Aviv University Ltd.
- From Israel
- Responsive
- Innovative Products and Technologies
Summary of the technology
Phages displaying Tie2 inhibitory peptides exert anti-angiogenic and anti-tumorigenic activities
IN administration of phages significantly inhibits orthotopic brain and lung tumors and improves survival rate
As lung cancer is the primary source of secondary brain tumors, a dual role for IN phages administration is implied
Project ID : 10-2013-454
Details of the Technology Offer
Cancer Therapy via Intranasal Administration of Filamentous Phages
We have shown that Ff phages administered via the intranasal route accumulate rapidly (within minutes) in the brain, lungs and stomach of mice and remain intact. To note, intranasal administration is a non-invasive approach for delivering compounds directly to the central nervous system (CNS) and lungs. Drugs administered through the intranasal route avoid hepatic first pass metabolism and can bypass the blood brain barrier (BBB) which often blocks access of drugs from the blood stream to the CNS.
In addition, we discovered that Ff phages can interact with Tie2, a tyrosine kinase receptor predominantly expressed on the surface of endothelial cells, and inhibit endothelial cell activity, angiogenesis and tumor growth. These findings correlate with other studies showing that Ff phages can act as immunomodulators and skew tumor associated macrophages (TAM’s) polarization towards the anti-angiogenic and anti-tumorigenic M1 phenotype, leading to infiltration of cytotoxic neutrophils into the tumor microenvironment which ultimately results in tumor rejection.
This technology can be used fortreating brain and lung malignancies via intranasal administration of Ff phages.